Clinical Response in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma, May Be Influenced by Characteristics of the Pretreatment Tumor Microenvironment (TME)

Authors :: Sattva S. Neelapu
Jérôme Galon
Armin Ghobadi
Yi Lin
William Y. Go
Lazaros J. Lekakis
Frederick L. Locke
Caron A. Jacobson
Sarah Turcan
David B. Miklos
John M. Rossi
Corinne Danan
Adrian Bot
Source :: Clinical Lymphoma Myeloma and Leukemia. 18:S281
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: 0301 basic medicine
Cancer Research
Tumor microenvironment
business.industry
Hematology
medicine.disease
03 medical and health sciences
030104 developmental biology
Oncology
Refractory
Cancer research
Medicine
In patient
business
B-cell lymphoma

Full Text Access

Tools